Access to accurate and timely diagnostic tests is not just a research concern—it’s a global healthcare problem. The Rapid and Portable Molecular Diagnostics Lab addresses this challenge by developing integrated, cost-effective, and miniaturized tools for point-of-care disease detection. Current approaches to nucleic acid testing often require extensive infrastructure and personnel, making them less feasible in remote or resource-limited settings. By harnessing microfluidics, biophysical modeling, and advanced biochemical assay design, the lab creates the next generation of molecular diagnostic platforms, such as smartphone-enabled nucleic acid detection systems and 3D-printable microfluidic architectures that efficiently deliver critical healthcare solutions to underserved communities.

The lab collaborates with clinicians, government agencies, and industry partners to translate these innovations into practical, robust platforms that can be rapidly deployed. It secures competitive research funding from NSF, DOD, and DOE to address diverse diagnostic needs—ranging from pandemic preparedness to point-of-care testing. By reducing barriers to reliable molecular diagnostics, the Rapid and Portable Molecular Diagnostics Lab aims to advance global health equity and empower communities with the tools needed for early disease detection and effective care.